A deal for Cosette to acquire Mayne Pharma has been terminated. The acquisition had been valued at $430 million, but the terms of the termination and the reasons behind it are unclear, with reports suggesting the Australian government may have rejected the deal due to national interest. The status of the acquisition had been previously reported as moving forward, with Cosette's intentions to expand into women's healthcare through the purchase.